Objective: Glucocorticoids are released in response to stress and alter cognition and brain function through both rapid nongenomic and slow genomic mechanisms. Administration of glucocorticoids in the form of hydrocortisone enhances aspects of learning and memory in individuals with PTSD but impairs these abilities in healthy individuals. We examine the time-dependent effects of glucocorticoids on cognition in HIV-infected men.
INTRODUCTION
Even in the era of combination antiretroviral therapy (cART), HIV-infected individuals show deficits in executive function, complex attention, processing speed, learning, and memory. [1] [2] [3] Associated dysfunction of fronto-striatal networks 4 and alterations in hippocampal and prefrontal brain regions [5] [6] [7] may reflect the distribution of HIV-related neuropathology, neuroinflammation, and/or selective neuronal vulnerability to HIV-mediated damage in these regions. [8] [9] [10] [11] [12] The hypothalamic-pituitary-adrenal (HPA) axis may also be an important contributor to HIV-associated cognitive manifestations. As a key mediator of the effects of stress on the hippocampus and prefrontal cortex, the HPA axis exerts cognitive effects by release and action of its primary steroid hormone, cortisol. 13 HIV-infected compared with HIVuninfected individuals demonstrate HPA axis alterations which may contribute to their cognitive difficulties including elevated basal cortisol levels, [14] [15] [16] [17] [18] [19] attenuated diurnal cortisol variations, 19 and reduced cortisol responsivity to challenges. 20 Thus, investigations into the causal role of the HPA axis in HIV-associated cognitive perturbations may indicate its importance as an additional treatment target.
Pharmacologic challenge studies with hydrocortisone, the exogenous form of cortisol, allow for evaluation of the direct link between the HPA axis and cognition in HIV, independent of psychological stress. Although no studies to date have evaluated the effects of hydrocortisone on cognition in HIV, low-dose hydrocortisone (LDH) enhances aspects of learning and memory in PTSD, [21] [22] [23] [24] has no effect in current depression, 25, 26 and often impairs these abilities in healthy individuals 27 although these effects are dependent on the timing of assessments in relation to LDH administration. [27] [28] [29] Traditionally, LDH effects on cognition are studied approximately 30-45 minutes post-LDH administration. This approach models the physiological effects of acute stressors on cognition and addresses the immediate rapid effects of LDH. Recent studies; however, have assessed cognition 4 hours post-LDH administration to examine the delayed slow effects of LDH, effects that are attributable to genomic factors. The 4-hour assessment is clinically meaningful as it occurs postpeak, when cortisol levels are steady and typical of the broader daily cortisol profile in individuals treated with LDH. 30 In a randomized double-blind placebo-controlled crossover design, 45 HIV-infected men received 10 mg of hydrocortisone (LDH), a widely used dose in previous cognitive studies, 28, 31, 32 or placebo before testing which occurred 30 minutes and 4 hours postpill administration. We hypothesized that LDH relative to placebo would impair learning and memory at both time points. Given LDH may affect cognition by inducing immune change, 33, 34 we also examined whether any cognitive changes were related to immune changes.
METHODS

Participants
Participants were recruited through HIV primary care clinics and the surrounding community through advertisements/ websites. Inclusion criteria were confirmed HIV seropositive by medical record, age 18-45 years, English as a first language, and use of same cART . 3 months. Exclusion criteria were Diagnostic and Statistical Manual of Mental Disorders, 4th Edition Structural Clinical Interview of Mental Health Disorders diagnosis of mood disorders in the past year or history of anxiety/psychotic disorders, current use of psychiatric medications; reported neurological conditions impacting cognition (eg, stroke), Body mass index . 40, history of substance abuse/ dependence in the past 6 months excluding alcohol/nicotine, and inability to abstain from illicit substances 24 hours before testing by urine toxicology screen.
Procedures
Qualifying participants visited UIC for an initial visit (session 1) and provided informed consent, completed a DSM Structural Clinical Interview of Mental Health Disorders interview, vitals assessment, toxicology screen, and questionnaires including Childhood Trauma Questionnaire, 35 Schedule of Life Events checklist, 36 PTSD Checklist-Civilian version, 37 Perceived Stress Scale (PSS-10), 38 Center for Epidemiologic Studies Depression Scale, 39 Pittsburgh Sleep Quality Index, 40 and Medication Adherence Self-Report Inventory. 41 Forty-five HIV-infected men (Table 1 ) returned for 2 parallel visits (sessions 2 and 3) nested in a randomized double-blind placebo-controlled crossover pharmacologic challenge study. UIC's Investigational Drug Service randomized participants to receive either LDH or placebo at session 2; opposite treatment at session 3. Sessions 2 and 3 entailed a toxicology screen, blood draw, vitals assessment, questionnaires, cognitive assessments, and collection of saliva samples. Session 2 occurred within 1 week of session 1 and session 3 occurred ;1 month after session 2. Sessions 2 and 3 
Cognitive Measures
Learning/memory: Hopkins Verbal Learning Test (HVLT-R; learning outcome = trial 1 learning, total learning; memory = delayed recall) 43 ; Attention/concentration: WAIS IV Letter-Number Sequencing (LNS) control condition (outcome = total correct), 44 Trail Making Test (TMT) part A (outcome = time to completion), 45 and congruent trials on the computerized Stroop (outcome = accuracy) 46 ; Executive function: LNS experimental condition (outcome = total correct), 44 TMT Part B (outcome = time to completion), 45 and incongruent Stroop trials (outcome = accuracy); and Visuospatial ability: Repeatable Battery for the Assessment of Neuropsychological Status Line Orientation (outcome = total correct). 47 The battery administered 30-minute postpill administration included HVLT, LNS, TMT, Stroop, and Repeatable Battery for the Assessment of Neuropsychological Status (administration time = 35-45 minutes); 4 hours postpill administration included HVLT, LNS, and TMT (administration time = 35-45 minutes). Four alternate versions of HVLT, LNS, and TMT were used to minimize carryover effects [48] [49] [50] ; all forms were counterbalanced. Stroop was only administered 30 minutes postpill administration because of greater susceptibility to practice effects. 50 
Physiological and Psychological Measures
During Sessions 2 and 3, salivary samples were taken 35 and 20 minutes prepill administration and 30, 60, 90, 180, 210, 240, 270, and 300 minutes postpill administration. 31, 32, 35 Saliva was collected through straws into Nalgene tubes, stored at 280 degrees, and samples were batch shipped to Salimetrics and assayed for cortisol (EIA kit, sensitivity ,0.007 mg/dL).
For cytokines, saliva was collected 20 minutes prepill administration and 30 and 240 minutes postpill administration. We computed the median cytokine value across 3 saliva samples from the placebo day 51 and change from the median cytokine value during placebo to acute and delayed time points during the LDH session [(placebo 2 LDH acute)/placebo)].
We assessed IL-6, TNF-a, IL-8, IL-1b, CRP, macrophage migration inhibitory factor, chemoattractants interferon gamma-induced protein 10 (IP-10), monocyte chemotactic protein-1, monokine induced by interferon, cell surface receptor tumor necrosis factor (TNF) receptor type 2, matrix metalloproteinase MMP-9, and MMP-2. Saliva was batch assayed in duplicate using a MILLIPLEX MAP human high sensitivity T-cell panel immunology multiplex assay (Millipore, Billerica, MAMillipore) for IL-1b, IL-6, IL-8, and TNFa (standard curves 0.18-7500 pg/mL; average interplate CV 9.9%); MILLIPLEX MAP standard sensitivity cytokine for IP-10 and monocyte chemotactic protein-1 (3.2-10,000 pg/mL; average interplate CV 9%); R&D systems (Minneapolis, MN) singleplex to detect TNF receptor type 2 (12-50,000 pg/mL; average interplate CV 5.75%), and R&D systems custom 5-plex for CRP, MIP, monokine induced by interferon, MMP-2, and MMP-9 (144-96,000 pg/mL; average interplate CV 12.7%). Milliplex results were acquired on a Labscan 200 analyzer (Luminex, Austin, TX) using Bio-Plex manager software 6.1 (Bio-Rad, Hercules, CA). Undetectable samples were assigned one-half the lowest detectable value. Cytokine values were log transformed because of non-normality.
Concurrent with saliva sampling, participants completed the 6-item State-Trait Anxiety Inventory and a 2-item Visual Analog Scale measuring how "anxious" and "stressed" participants felt.
Statistical Analysis
Mixed-effects regressions (random intercept) were conducted in SAS (v.9.4 for Windows) to examine LDH effects on physiological, psychological, and cognitive measures. For cortisol/psychological measures, predictors were Treatment (LDH, placebo), Time (treated categorically), and Treatment · Time interaction. For cognition, predictors included Treatment, Time (Acute, Delayed), and Treatment · Time interaction. Models adjusted for sequence of cognitive testing forms and treatment sequence to account for potential bias because of carryover effects. Mixed-effects regressions also were used to 
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Correlations were conducted to determine whether cognitive changes (LDH-placebo) and/or immune changes were associated with cortisol responsivity to LDH (computed area under the curve-AUC 52 ). Exploratory correlations were conducted between individual difference factors (Childhood Trauma Questionnaire, PSS-10, PTSD Checklist-Civilian version, Center for Epidemiologic Studies Depression Scale-D, SLE), HIV-related clinical characteristics (CD4 count, viral load), and AUC. Factors correlating with AUC were examined in a series of multivariable linear regressions to determine whether those factors mediated cognitive changes by their effects on cortisol responsivity to LDH. 53, 54 
RESULTS
Mean salivary cortisol levels at 30 and 45 minutes before LDH and placebo (ie, baseline) was 0.20 mg/dL (5.1 nmol/L). Levels changed across study duration during LDH but not placebo. Compared with baseline, levels increased at 105 and 150 minutes post-LDH administration (P's , 0.001), the time frame when the "acute" cognitive battery was administered. Cortisol levels returned to baseline levels at the 315 and 360 minutes time points after LDH (P's . 0.68), the time frame when the "delayed" cognitive assessment was obtained. Self-reported anxiety and stress levels remained stable across study duration and session (P's . 0.88). IL-8 and MMP-2 decreased from baseline with LDH at the 30-minute time point (P's , 0.05).
Participants showed significant improvement only in learning after receiving LDH compared with placebo at the 30-minute time point (Table 2 ). There were no effects of LDH on any outcome at the 4-hour time point. At the 30-minute time point, the greater the increase in cortisol after LDH, the better the scores on trial 1 (r = 0.35, P = 0.02) and total learning (r = 0.38, P = 0.01) during LDH relative to placebo. Associations remained after controlling for cortisol levels during placebo (P's , 0.05). Changes in IL-8 or MMP-2 did not correlate with acute learning changes.
More stressful life events (r = 0.32, P = 0.03) and greater emotional abuse (r = 0.30, P = 0.04) were associated with greater increases in cortisol after LDH but not placebo. Although these measures were not related to learning, mediational analyses indicated that stressful events influenced changes in total learning indirectly through cortisol responsivity to LDH [97% of the total effect (12%) was explained by the indirect effect]. The same pattern was seen with childhood emotional abuse [98% of the total effect (11%) was explained by the indirect effect]. CD4 count and viral load were not associated with LDH cortisol changes (P's . 0.36).
DISCUSSION
Our primary goal was to examine the time-dependent effects of LDH on cognition in HIV-infected men. Secondary goals were to examine the mechanisms underlying these effects and determine who might benefit most from LDH. We demonstrated that relative to placebo, LDH has only acute cognitive enhancing effects. The benefit was observed on measures of learning but not memory, attention/concentration, executive function, or visuospatial abilities. The enhancement was observed in the early but not later time point, and the magnitude of the enhancement was associated with the magnitude of cortisol response. Those findings suggest that LDH may work acutely through nongenomic mechanisms to normalize stress-induced alterations in the HPA axis and enhance learning in HIV-infected men. Those who showed the greatest cognitive enhancement had more stressful life events and a greater degree of emotional abuse those showing less enhancement. Mediational analyses revealed that the association between these individual difference factors and cognition was due to the individual differences in cortisol response after LDH. Thus, HIVinfected men experiencing more stress/trauma may showed the greatest acute cognitive benefits from LDH because LDH in these men may increase glucocorticoids to levels supporting learning. Our findings provide further evidence that the cognitive effects of LDH depend on dose, administration timing, cognitive domains assessed, and mental health factors. 21, 27 Although participants had no history of PTSD, they reported above-average levels of stress compared with healthy men in other studies 55 and exposure to violence/abuse. Broadly, our findings of acute LDH learning improvements are consistent with studies in PTSD. 23, 24 Although we did not find improvements in attention and working memory which others have demonstrated, 56 those changes were noted 75 minutes post-LDH in PTSD. 21, 22 We did not test during this time frame, therefore it is possible that learning remains elevated for some time and that other abilities might be enhanced at that time point. The generalizability of these findings across different doses and duration and to the broader population of HIV warrants further study.
In sum, administration of LDH in HIV-infected men increased cortisol and enhanced learning acutely but not in the longer term. The absence of cognitive benefit in the delayed time point, when cortisol levels returned to baseline, indicates that LDH may have limited clinical utility for treating cognitive impairments in HIV-infected men. However, our findings provide insights into mechanisms and individual difference factors underlying the effects of acute glucocorticoids on learning.
